| Pentavalent human-bovine reassortant vaccine (RV5, PRV) | Attenuated human rotavirus vaccine (RV1, HRV) | |
| Trade name | RotaTeq | Rotarix |
| Serotypes contained | G1, G2, G3, G4, P1[8] | G1P[8] |
| Dose | 2 mL | 1 mL |
| Administration | Ready-to-use | Two formulations: one is ready to use; one requires reconstitution |
| Number of doses | 3 | 2 |
| Recommended schedule | 2, 4, 6 months | 2, 4 months |
| Minimum age first dose | 6 weeks | 6 weeks |
| Maximum age first dose | ||
| United States | 14 weeks, 6 days | 14 weeks, 6 days |
| Europe | 12 weeks | 12 weeks |
| Minimal interval between doses | 4 weeks | 4 weeks |
| Maximum age last dose | ||
| United States | 8 months, 0 days | 8 months, 0 days |
| Europe | 24 weeks | 24 weeks |
| Oral applicator | Latex-free | Contains latex* |
| Contains thimerosal | No | No |
